oral glp-1 medications The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro Dry Mouth Relief for GLP-1

Clinical assessments were conducted every 3 months to evaluate efficacy, measured as percentage of total weight loss (%TWL), excess weight loss (%EWL), changes in BMI, and improvement in comorbidities, as well as tolerance, monitored for adverse effects including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and discontinuation rates

The company has already shared some late-stage data on that drug, but the most important trial is one studying the treatment specifically for weight loss

Moreover, the adoption is being accelerated by favorable regulatory approvals and an increased focus on integrated cardiometabolic care

Introduction of Generics and Oral Formulations: Market accessibility has improved through the approval of the first generic liraglutide (Victoza) earlier this year and generic exenatide last month

PwC reports that the next segment of the obesity drug market will most likely be characterized by expanded indications, more patient-friendly delivery formats and therapies with stronger adherence profiles

Found offers both brand-name and compounded GLP1s with insurance navigation and a multidisciplinary care team